Dermatology Outsource Medical Billing

Why Are Dermatology Practices Switching RCM Vendors Before Year-End Contract Renewals in 2026?

Published Date : Sep 03, 2026 Last Updated : Sep 03 2026 6 min read

Dermatology practices reviewing their billing vendor contracts this quarter are not doing so out of routine, they are racing a federal rule change that lands the same month most vendor agreements auto-renew.

Every fall, practice administrators treat vendor renewal as a formality: review the invoice, sign the extension, move on. That pattern breaks in 2026. CMS released the CY2027 Physician Fee Schedule proposed rule in July, comments close in mid-September, and the final rule is expected in November, the same quarter most multi-year RCM contracts require written notice to avoid automatic renewal.

For dermatology practices, the timing is not incidental. The proposed rule's biggest structural change targets exactly the billing pattern that drives dermatology revenue: an evaluation and management visit billed alongside a same-day procedure.

A note on where this stands today: CMS-1848-P is a proposed rule, not a final one. The Modifier -25 mechanics, the specialty-level impact estimate, and the conversion factor figures can all shift before the final rule publishes in November. What will not shift is the calendar. The comment period, the expected final rule timing, and most vendor contracts' notice windows all fall in the same several weeks.

The decision practices actually face this quarter is not whether the current estimate holds exactly, it is whether their vendor can adapt quickly once the final numbers land, and whether their contract still gives them the option to find out before signing another term.

The Three Pillars of Dermatology RCM Vendor Readiness Before Year-End Renewal

This breakdown builds on the framework laid out in our pillar guide, Best Medical Billing Services in the US: The Complete RCM Buyer's Guide, applied specifically to what dermatology practices need to check before a Q4 2026 renewal.

Pillar One: Modifier -25 Exposure on Biopsy-Heavy Encounters CMS's CY2027 Physician Fee Schedule proposed rule (CMS-1848-P) targets same-day E/M-plus-procedure billing directly. That is the exact pattern behind most dermatology encounters, where a lesion biopsy, destruction, or excision is billed alongside an evaluation and management visit.

Under the proposal, the lower-valued service on that claim would be reimbursed at half rate instead of full rate, and industry impact estimates place dermatology among the specialties facing the steepest percentage reduction if the rule finalizes as written. A vendor still coding and appealing under current logic has no mechanism to catch this before the January 1, 2027 effective date, and by the time the first denial pattern shows up in a monthly report, an entire quarter of claims has already been billed the old way.

Pillar Two: Skin Substitute Reclassification Already Live Since January 1, 2026, CMS has classified most skin substitute products as incident-to supplies rather than separately payable biologics, replacing prior per-product rates with a single national per-square-centimeter rate. For dermatology groups performing wound closure and grafting procedures, this changed the charge capture logic mid-cycle, not at a convenient contract boundary.

A vendor that has not rebuilt its fee schedule and documentation workflow around this reclassification is under-billing every claim that touches it, and because the change is already in effect, the leakage is compounding with every claim cycle rather than sitting on the horizon like the 2027 proposal.

Pillar Three: The Contract Clock Nobody Reads Until It's Too Late Most RCM vendor agreements carry 90 to 120-day auto-renewal notice windows. That means a contract set to renew January 1, 2027 typically requires written notice sometime between September and October 2026, the same window as the CMS comment deadline on the proposed rule and roughly one month before the final rule is expected.

Practices that miss the notice deadline lock themselves into another full contract term with a vendor unprepared for changes that take effect the day the new term begins. That sequencing is what turns a routine renewal into a genuine decision point: sign now, before the final rule details are even public, or hold the vendor to a documented readiness standard before committing to another term.

What Happens If You Renew Without an Audit First

Renewal Path	Generic RCM Vendor	Internal Billing Team	MBC Revenue Integrity Partner
Modifier -25 Readiness	Reactive appeals after denial	Ad hoc, no rule tracking	Gaps quantified and closed before the effective date
Skin Substitute Billing	Legacy per-product rates still in use	Manual spreadsheet tracking	Leakage identified and corrected at the charge level
Payer-Specific LCD Mapping	Generalist, not derm-specific	Limited to top payer only	Built into standing dermatology billing protocols
Contract Terms	Multi-year lock-in, exit penalties	Not applicable	No long-term lock-in; performance is the retention strategy

The Renewal Decision Timeline

Date	Event	Why It Matters to Your Contract
September 14, 2026	CMS comment deadline on CMS-1848-P	Last window to weigh in before rule mechanics are finalized
September–October 2026	Typical 90–120 day vendor notice window	Missing this locks you into another full term
November 2026	CY2027 PFS final rule expected	Modifier -25 and conversion factor numbers become fixed
January 1, 2027	Effective date	New billing logic applies to every claim from day one

MBC Spotlight: Auditing Before You Sign Anything

MBC's dermatology-specific coders build documentation protocols around Modifier -25 exposure and skin substitute charge capture before a rule takes effect, not after the first denial arrives. This is the same disciplined, mechanism-level approach detailed in our review of dermatology overbundling patterns, applied here to a regulatory deadline instead of a coding pattern.

Our Complimentary Revenue Diagnostic quantifies exactly where your current vendor's readiness gaps sit against all three pillars, giving your CFO a documented case for renewal, renegotiation, or transition before the notice window closes, without requiring your team to build that audit internally.

With 25+ years of multi-specialty billing experience and a 97% clean claim rate across our dermatology book of business, MBC structures every engagement with no long-term lock-in, so performance, not a contract penalty, is what keeps a client with us. Clients who move to MBC average a 30% reduction in Days in AR within 90 days, and our 98% client retention rate reflects results rather than exit friction built into the contract itself.

For practices weighing whether their current platform can handle both changes, our breakdown of dermatology EHR-bundled billing and our full vendor switching checklist and timeline both walk through what a clean transition actually requires before the notice deadline arrives.

Key Takeaways

The CY2027 Physician Fee Schedule proposed rule directly affects same-day E/M-plus-procedure billing, the core pattern in dermatology encounters.
Skin substitute reclassification took effect January 1, 2026, and many legacy fee schedules have not been rebuilt around it.
Vendor contract notice windows typically fall in the same September–October period as the CMS comment deadline, making Q4 2026 a decision point, not a routine renewal.
An audit before renewal gives practice administrators and CFOs a documented, quantified basis for the renewal decision.

Frequently Asked Questions

CMS-1848-P is the proposed Medicare Physician Fee Schedule for calendar year 2027, released July 14, 2026, and it includes a proposed change to how same-day evaluation and management visits are paid alongside procedures. Because dermatology relies heavily on billing an E/M visit with a same-day biopsy, destruction, or excision, this proposal has an outsized impact on the specialty compared to many others, with industry estimates placing the specialty-level effect near a 9 percent reduction if finalized as proposed.

Most vendor agreements require written notice 90 to 120 days before the renewal date, which for a January 1, 2027 renewal typically falls between September and October 2026. Practice administrators should confirm their specific contract's notice requirement now, since missing that window means another full contract term regardless of vendor performance.

Since January 1, 2026, most skin substitute products are billed as incident-to supplies at a single national per-square-centimeter rate rather than under prior per-product biologic payment methods. Practices performing wound closure or grafting procedures need their vendor's fee schedule and documentation workflow updated to this logic, or claims risk being billed under outdated rate assumptions.

Ask whether the vendor has documented protocols for Modifier -25 exposure under the proposed 2027 rule, updated billing logic for skin substitute reclassification, and payer-specific LCD mapping for the practice's top payers rather than generalist billing rules. Also confirm the contract's notice period and whether early termination carries a penalty.

A well-managed transition, timed to a renewal date rather than mid-cycle, is designed to avoid a disruption to cash flow, since the outgoing vendor completes work-in-progress claims while the incoming vendor is credentialed and onboarded in parallel. The disruption risk is typically lower than the cost of another contract term with an underperforming vendor.

Debbie Young

A Subject Matter Expert in healthcare billing operations with nearly 10 years of experience, sharing insights on claims processing, coding support, and revenue cycle optimization. Dedicated to educating healthcare professionals on compliance, accuracy, and strategies to improve billing performance.